Sign in
Active, not recruitingNo phase

Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation

Key facts

Who runs it
University of Luebeck
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
114 people enrolled
Started
17 Mar 2022
Expected to end
30 Jun 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • autologous PRP (platelet rich plasma)
  • Saline solution (NaCL) Injection
Record updated
4 June 2025

Who can take part

Age
18 years to 42 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Serum AMH < 0.5 ng/ml (at screening visit and in the absence of OC or sex-steroid intake)
  • Antral follicular count (AFC) in both ovaries ≤ 5 (at screening visit and in the absence of OC or sex-steroid intake)
  • Spontaneous cycle, menstrual cycle length 21-35 days
  • Body mass index (BMI) ≥18 kg/m2 and ≤38 kg/m2
  • Both ovaries must be visible by transvaginal ultrasound examination
  • Both ovaries must be judged accessible by transvaginal puncture
  • Indication for IVF or ICSI treatment
  • Willingness to participate and provide written consent prior to initiation of any study-related procedures
  • The subject and male partner must agree to participate in the infant follow-up if she becomes pregnant
  • The subject must be able to communicate well with the investigator and research staff and to comply with the requirements of the study protocol

Who cannot take part

  • ≥ four cumulus-oocyte-complexes (COCs) retrieved in a previous IVF cycles with a conventional stimulation protocol (within 6 months before enrollment)
  • Oral contraceptive or sex steroid intake within 1 month prior to enrollment
  • Contraindication for transvaginal ovarian puncture (such as previous major lower abdominal surgery and known severe pelvic adhesion)
  • Relevant autoimmune disease
  • History of malignancy and systemic chemotherapy or pelvic radiation
  • Relevant endocrine disorders such as hypothalamic-pituitary disorder or thyroid dysfunction (except substituted Hashimoto's thyroiditis or latent hypothyroidism)
  • Relevant thrombophilic disorder
  • Serum value of FSH ≥25 IU/l (within 12 months measured in the absence of OC or hormone replacement intake)
  • Thrombocytopenia defined as < 100.000 platelets/µl at screening
  • Presence of structural or numerical chromosomal abnormality in cytogenetic analysis
  • Severe endometriosis (stage III-IV)
  • Ovaries located outside the inner pelvis
  • Presence of unilateral or bilateral hydrosalpinx
  • Contraindication for pregnancy
  • Uterine malformations or pathologies (such as sub mucosal fibroid(s), endometrial hyperplasia, endometrial fluid accumulation, or endometrial adhesions)
  • Mental disability or any other lack of fitness, in the investigator's opinion, to preclude subjects in or to complete the study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The primary objective is to investigate the efficacy, defined as an increase in oocyte numbers upon ovarian stimulation, and safety of a single intra-ovarian PRP injection vs. saline solution (NaCl) injection (Placebo) transvaginally or laparoscopically for follicular activation in patients with child wish and with low ovarian reserve/expected poor ovarian response planning to undergo IVF or ICSI using own eggs. Pain score as numerical rating score and validated quality of life questionnaire will be requested after the procedure. Longterm follow-up of all participants will be performed 1, 2 and 5 years after end of study.

The 2 groups in the trial

  • Autologous intra-ovarian PRP injectionTreatment being tested

    Study group, treated with autologous intra-ovarian PRP injection and undergoing a subsequent fresh ET-IVF/ICSI cycle in the third cycle after intervention

    Treatment: autologous PRP (platelet rich plasma)

  • intra-ovarian saline solution (NaCL) injectionPlacebo, for comparison

    Control group, treated with intra-ovarian NaCl injection and undergoing a subsequent fresh ET-IVF/ICSI cycle in the third cycle after intervention

    Treatment: Saline solution (NaCL) Injection

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Efficacy and Safety of Intra-ovarian PRP Injection Within a Prospective, Single-blinded, Placebo-controlled, Randomized, Clinical Superiority Trial in Subjects With Low Ovarian Reserve/Expected Poor Ovarian Response
Record updated
4 June 2025